Loading company
Regenxbio Inc.
RGNX · Nasdaq · ·
Next earnings: November 5, 2026
$7.44-0.6%Sep 29 close
- 1M
- -23.0%
- 6M
- -4.3%
- 1Y
- -23.0%
- 5Y
- -83.0%
RGNX · Nasdaq · ·
Next earnings: November 5, 2026
$7.44-0.6%Sep 29 close
Regenxbio Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $108M | $21.4M | +405.73% |
| Profit | $22.7M | -$70.9M | +132.04% |
| Profit per share | $0.43 | -$1.38 | +131.16% |
| Free Cash Flow | -$63M | -$49.7M | -26.67% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our second quarter was defined by strong clinical execution across our pipeline: the Phase III AFFINITY DUCHENNE ® trial met its primary endpoint, we dosed the first participant in the NAAVIGATE study in diabetic retinopathy, and the FDA reaffirmed the path forward for RGX-121,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from Regenxbio Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Regenxbio Inc. has no earnings call transcript available.